Severity Over Time of Early Forms of Spondyloarthritis

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Feb 8, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the progression of a condition called spondyloarthritis (SpA), which is a type of chronic inflammation that affects the joints and spine. Researchers want to find out what factors might lead to more severe disease over time. By identifying these factors early, they hope to treat patients more effectively and help them achieve remission, which means having little to no symptoms of the disease.

To participate in this study, individuals need to be over 18 years old and have been diagnosed with spondyloarthritis by a specialist, with symptoms lasting less than two years. The trial is not currently recruiting participants, but once it starts, those who qualify can expect to provide informed consent and participate in assessments that will help researchers learn more about this condition. It's important to note that people with certain other health conditions or those who don’t wish to participate will not be included in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age \>18 years;
• • Diagnosis of SpA confirmed by the rheumatologist with duration of symptoms \<
• • 2 years;
• • Signature of the written informed consent to the study
• Exclusion Criteria:
• • Age \< 18 years;
• • Patients suffering from other rheumatic pathologies (even in overlap), or genetic diseases such as Marfan syndrome, Ehlers Danlos syndrome
• • Any medical or psychiatric condition that in the judgment of the investigator would prevent the participant from complying with the protocol or completing the study according to the protocol.
• • Refusal to sign the informed consent to the study.